References
- White A. Antipsychotics and the law. Australian and New Zealand Journal of Psychiatry 2001; 35: 541–542
- Remington G, Kapur S. Atypical antipsychotics: are some more atypical than others?. Psychopharmacology 2000; 148: 3–15
- Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annual Review of Medicine 2001; 52: 503–517
- Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal 2000; 321: 1371–1376
- Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research 1999; 35: 51–68
- Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: a new hypothesis. American Journal of Psychiatry 2001; 158: 360–369
- Seeman P, Corbett R, VanTol H. Atyipcal neuroleptics have a low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology 1997; 16: 93–110
- Peacock L, Solgaard T, Lublin H, Gerlach J. Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects. Psychopharmacology 1996; 124: 188–196
- Tollefson G D, Beasley CM, Jr, Tamura R N, Tran P V, Potvin J H. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. American Journal of Psychiatry 1997; 154: 1248–1254